Molecular Templates, Inc. (MTEM)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 1.43 Million USD | 95.95% |
| 2022 | -80.08 Million USD | -9.75% |
| 2021 | -72.94 Million USD | 19.78% |
| 2020 | -99 Million USD | -116.97% |
| 2019 | -66.02 Million USD | -52.09% |
| 2018 | -28.32 Million USD | -128.67% |
| 2017 | -22.13 Million USD | 45.7% |
| 2016 | -10.55 Million USD | -190.47% |
| 2015 | 27.93 Million USD | 186.17% |
| 2014 | -31.25 Million USD | -40.81% |
| 2013 | -24.51 Million USD | -10.97% |
| 2012 | -19.99 Million USD | 40.95% |
| 2011 | -30.03 Million USD | -18.57% |
| 2010 | -18.17 Million USD | -33.96% |
| 2009 | -20.63 Million USD | -19.8% |
| 2008 | -17.29 Million USD | 43.15% |
| 2007 | -31.31 Million USD | 46.31% |
| 2006 | -59.25 Million USD | -26.89% |
| 2005 | -46.53 Million USD | -290.73% |
| 2004 | -23.97 Million USD | 394.43% |
| 2003 | -8.18 Million USD | -230.84% |
| 2002 | -2.47 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 1.1 Million USD | 141.74% |
| 2024 Q2 | -7.22 Million USD | -736.97% |
| 2023 FY | - USD | 95.95% |
| 2023 Q3 | 5.13 Million USD | 154.85% |
| 2023 Q1 | 12.24 Million USD | 159.32% |
| 2023 Q2 | -9.36 Million USD | -176.52% |
| 2023 Q4 | -4.08 Million USD | -179.6% |
| 2022 FY | - USD | -9.75% |
| 2022 Q1 | -18.68 Million USD | -100.94% |
| 2022 Q2 | -23.65 Million USD | -26.56% |
| 2022 Q4 | -20.63 Million USD | 4.22% |
| 2022 Q3 | -21.54 Million USD | 8.92% |
| 2021 FY | - USD | 19.78% |
| 2021 Q2 | -13.2 Million USD | 49.74% |
| 2021 Q3 | -27.66 Million USD | -109.43% |
| 2021 Q4 | -9.3 Million USD | 66.38% |
| 2021 Q1 | -26.27 Million USD | -1.79% |
| 2020 FY | - USD | -116.97% |
| 2020 Q1 | -21.66 Million USD | -39.5% |
| 2020 Q2 | -28.93 Million USD | -33.54% |
| 2020 Q3 | -21.49 Million USD | 25.7% |
| 2020 Q4 | -25.81 Million USD | -20.09% |
| 2019 Q1 | -5.69 Million USD | 10.34% |
| 2019 Q3 | -15.41 Million USD | -76.52% |
| 2019 Q4 | -15.53 Million USD | -0.74% |
| 2019 FY | - USD | -52.09% |
| 2019 Q2 | -8.73 Million USD | -53.39% |
| 2018 Q3 | -4.58 Million USD | 53.1% |
| 2018 FY | - USD | -128.67% |
| 2018 Q4 | -6.35 Million USD | -38.46% |
| 2018 Q1 | -8.96 Million USD | -20.14% |
| 2018 Q2 | -9.78 Million USD | -9.14% |
| 2017 Q2 | -715 Thousand USD | 80.95% |
| 2017 Q1 | -3.75 Million USD | 24.38% |
| 2017 FY | - USD | 45.7% |
| 2017 Q4 | -7.45 Million USD | -795.44% |
| 2017 Q3 | -833 Thousand USD | -16.5% |
| 2016 Q1 | -8.43 Million USD | -116.15% |
| 2016 Q4 | -4.96 Million USD | 3.89% |
| 2016 FY | - USD | -190.47% |
| 2016 Q3 | -5.16 Million USD | 10.78% |
| 2016 Q2 | -5.78 Million USD | 31.41% |
| 2015 Q2 | -8.67 Million USD | -11.19% |
| 2015 FY | - USD | 186.17% |
| 2015 Q4 | 52.25 Million USD | 901.12% |
| 2015 Q3 | -6.52 Million USD | 24.82% |
| 2015 Q1 | -7.8 Million USD | -3.35% |
| 2014 Q4 | -7.55 Million USD | -8.12% |
| 2014 FY | - USD | -40.81% |
| 2014 Q1 | -9.67 Million USD | -27.34% |
| 2014 Q2 | -13.79 Million USD | -42.56% |
| 2014 Q3 | -6.98 Million USD | 49.35% |
| 2013 FY | - USD | -10.97% |
| 2013 Q1 | -2.62 Million USD | 56.13% |
| 2013 Q2 | -799 Thousand USD | 69.61% |
| 2013 Q3 | -11.16 Million USD | -1297.87% |
| 2013 Q4 | -7.59 Million USD | 31.99% |
| 2012 Q1 | -7.12 Million USD | 34.01% |
| 2012 Q3 | -6.61 Million USD | 70.51% |
| 2012 FY | - USD | 40.95% |
| 2012 Q2 | -22.42 Million USD | -214.94% |
| 2012 Q4 | -5.99 Million USD | 9.38% |
| 2011 FY | - USD | -18.57% |
| 2011 Q4 | -10.79 Million USD | 4.49% |
| 2011 Q1 | -7.3 Million USD | -31.05% |
| 2011 Q3 | -11.29 Million USD | -108.62% |
| 2011 Q2 | -5.41 Million USD | 25.88% |
| 2010 Q4 | -5.57 Million USD | 8.37% |
| 2010 Q1 | -5.59 Million USD | -3.42% |
| 2010 FY | - USD | -33.96% |
| 2010 Q2 | -11.53 Million USD | -105.93% |
| 2010 Q3 | -6.08 Million USD | 47.23% |
| 2009 FY | - USD | -19.8% |
| 2009 Q4 | -5.41 Million USD | -7.1% |
| 2009 Q3 | -5.05 Million USD | 4.03% |
| 2009 Q2 | -5.26 Million USD | -5.53% |
| 2009 Q1 | -4.99 Million USD | -7.01% |
| 2008 FY | - USD | 43.15% |
| 2008 Q3 | -4.42 Million USD | -202.84% |
| 2008 Q4 | -4.66 Million USD | -5.47% |
| 2008 Q2 | 4.3 Million USD | 187.63% |
| 2008 Q1 | -4.9 Million USD | 33.9% |
| 2007 Q3 | -6.71 Million USD | -180.28% |
| 2007 Q4 | -7.42 Million USD | -10.53% |
| 2007 FY | - USD | 46.31% |
| 2007 Q1 | -9.34 Million USD | 7.03% |
| 2007 Q2 | 8.36 Million USD | 189.52% |
| 2006 FY | - USD | -26.89% |
| 2006 Q1 | -14.72 Million USD | 7.75% |
| 2006 Q4 | -10.05 Million USD | 41.64% |
| 2006 Q3 | -17.22 Million USD | -5.59% |
| 2006 Q2 | -16.31 Million USD | -10.79% |
| 2005 Q4 | -15.96 Million USD | -34.75% |
| 2005 Q1 | -7.66 Million USD | -119.18% |
| 2005 Q2 | -10.48 Million USD | -36.73% |
| 2005 FY | - USD | -290.73% |
| 2005 Q3 | -11.84 Million USD | -12.97% |
| 2004 Q4 | 39.97 Million USD | 850.02% |
| 2004 FY | - USD | 394.43% |
| 2004 Q3 | -5.33 Million USD | 0.0% |
| 2003 FY | - USD | -230.84% |
| 2002 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| America Great Health | -447.29 Thousand USD | 419.702% |
| Ampio Pharmaceuticals, Inc. | - USD | -Infinity% |
| Aridis Pharmaceuticals, Inc. | -29.5 Million USD | 104.846% |
| Biora Therapeutics, Inc. | -114.05 Million USD | 101.254% |
| Bio-Path Holdings, Inc. | -15.76 Million USD | 109.073% |
| Better Therapeutics, Inc. | -38.26 Million USD | 103.737% |
| Calithera Biosciences, Inc. | -38.26 Million USD | 103.737% |
| Comera Life Sciences Holdings, Inc. | -17.88 Million USD | 107.995% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | -33.73 Million USD | 104.239% |
| Eloxx Pharmaceuticals, Inc. | -33.37 Million USD | 104.285% |
| Evelo Biosciences, Inc. | -106.34 Million USD | 101.345% |
| Evolutionary Genomics, Inc. | -913.47 Thousand USD | 256.545% |
| Finch Therapeutics Group, Inc. | -32.48 Million USD | 104.402% |
| Galera Therapeutics, Inc. | -46.69 Million USD | 103.063% |
| Innovation1 Biotech Inc. | -5.68 Million USD | 125.159% |
| Kiromic BioPharma, Inc. | -16.3 Million USD | 108.772% |
| Navidea Biopharmaceuticals, Inc. | -13.87 Million USD | 110.306% |
| NexImmune, Inc. | -28.16 Million USD | 105.077% |
| Orgenesis Inc. | -60.71 Million USD | 102.355% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | 102.788% |
| Point of Care Nano-Technology, Inc. | -73.41 Thousand USD | 2047.804% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | 108.857% |
| Scopus BioPharma Inc. | -11.71 Million USD | 112.209% |
| Sorrento Therapeutics, Inc. | -539.92 Million USD | 100.265% |
| Statera Biopharma, Inc. | 38.93 Million USD | 96.327% |
| TRACON Pharmaceuticals, Inc. | -6.88 Million USD | 120.773% |
| Trevena, Inc. | -35.28 Million USD | 104.052% |
| Vaxxinity, Inc. | -56.05 Thousand USD | 2651.248% |
| Vaccinex, Inc. | -19.74 Million USD | 107.241% |
| Vicapsys Life Sciences, Inc. | -1.04 Million USD | 236.584% |
| Viracta Therapeutics, Inc. | -46.86 Million USD | 103.052% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | 119.689% |